Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34812850.
- Also identified by DOI 10.1001/jamanetworkopen.2021.37575 and PMC identifier 8611483.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study assesses the risk of breakthrough SARS-CoV-2 infection and hospitalization among fully vaccinated patients with multiple myeloma.
Medical subject headings
- COVID-19
- Hospitalization
- Multiple Myeloma
- Vaccination